BAYER AG
- Country
- ๐ฉ๐ชGermany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
A Study to Evaluate Cooling Sensation of an Allergy Product in Adults With a History of Allergies
- First Posted Date
- 2019-11-14
- Last Posted Date
- 2021-02-04
- Lead Sponsor
- Bayer
- Target Recruit Count
- 468
- Registration Number
- NCT04162795
- Locations
- ๐บ๐ธ
Focus Pointe Global, Teaneck, New Jersey, United States
Study to Compare the Effects of Drug Darolutamide and Drug Enzalutamide on Physical Function, Including Balance and Daily Activity, in Patients With Castration-resistant Prostate Cancer (CRPC)
- Conditions
- Prostatic Cancer, Castration-Resistant
- Interventions
- First Posted Date
- 2019-11-08
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- Bayer
- Target Recruit Count
- 30
- Registration Number
- NCT04157088
- Locations
- ๐บ๐ธ
Oregon Health and Science University, Portland, Maine, United States
๐บ๐ธDuke University Medical Center, Durham, North Carolina, United States
๐บ๐ธMidLantic Urology - Bala Cynwyd, Bala-Cynwyd, Pennsylvania, United States
A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein
- Conditions
- Cancers With HER2 Expression
- Interventions
- Drug: BAY2701439
- First Posted Date
- 2019-11-01
- Last Posted Date
- 2023-10-18
- Lead Sponsor
- Bayer
- Target Recruit Count
- 14
- Registration Number
- NCT04147819
- Locations
- ๐บ๐ธ
Johns Hopkins Hospital/Health System, Baltimore, Maryland, United States
๐บ๐ธMemorial Sloan-Kettering Cancer Center, New York, New York, United States
๐บ๐ธWashington University School of Medicine, Saint Louis, Missouri, United States
Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body
- Conditions
- Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion
- Interventions
- Drug: larotrectinib(Vitrakvi, BAY2757556)
- First Posted Date
- 2019-10-29
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Bayer
- Target Recruit Count
- 150
- Registration Number
- NCT04142437
- Locations
- ๐บ๐ธ
Banner Desert Medical Center, Mesa, Arizona, United States
๐บ๐ธCalifornia Research Inst., Los Angeles, California, United States
๐บ๐ธUSC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
Study to Gather Information on the Safety and Use of Aflibercept Injections Into the Eye for the Treatment of Eye Disorders in Mexican Routine Clinical Practice
- First Posted Date
- 2019-10-23
- Last Posted Date
- 2023-02-17
- Lead Sponsor
- Bayer
- Target Recruit Count
- 73
- Registration Number
- NCT04137120
- Locations
- ๐ฒ๐ฝ
Many locations, Multiple Locations, Mexico
Study to Find Out the Optimal Dose of Caffeine in the Combination Tablet of Naproxen Sodium and Caffeine in Patients Experiencing Moderate to Severe Pain After Having Wisdom Teeth Removed
- Conditions
- Pain, Postoperative
- Interventions
- First Posted Date
- 2019-10-18
- Last Posted Date
- 2021-09-01
- Lead Sponsor
- Bayer
- Target Recruit Count
- 193
- Registration Number
- NCT04132336
- Locations
- ๐บ๐ธ
JBR Clinical Research, Salt Lake City, Utah, United States
Study on the Effectiveness and Safety of the Combination of the Two Drugs Regorafenib and Nivolumab in Patients With Colorectal Cancer (Cancer of the Colon or Rectum Classified as Proficient Mismatch Repair and Microsatellite Stable)
- Conditions
- Colorectal Cancer
- Interventions
- Biological: Nivolumab (Opdivo)
- First Posted Date
- 2019-10-15
- Last Posted Date
- 2023-07-18
- Lead Sponsor
- Bayer
- Target Recruit Count
- 70
- Registration Number
- NCT04126733
- Locations
- ๐บ๐ธ
Northwest Cancer Specialists, PC, Vancouver, Washington, United States
๐บ๐ธMinnesota Oncology Hematology, PA, Minneapolis, Minnesota, United States
๐บ๐ธBaylor Charles A. Sammons Cancer Center at Dallas, Dallas, Texas, United States
Roll-over Study to Continue Treatment With the Investigational Drug Rogaratinib and to Further Test Its Safety
- First Posted Date
- 2019-10-14
- Last Posted Date
- 2022-04-01
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1
- Registration Number
- NCT04125693
- Locations
- ๐จ๐ญ
Kantonsspital St. Gallen, St. Gallen, Sankt Gallen, Switzerland
A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described
- Conditions
- Prostate Cancer
- Interventions
- Drug: Darolutamide(Nubeqa, BAY1841788)
- First Posted Date
- 2019-10-10
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Bayer
- Target Recruit Count
- 805
- Registration Number
- NCT04122976
- Locations
- ๐บ๐ธ
Urology San Antonio, San Antonio, Texas, United States
๐บ๐ธUrology Centers of Alabama, Homewood, Alabama, United States
๐บ๐ธArizona Institute of Urology, Tucson, Arizona, United States
Burden of Ischemic Stroke and Intake of Oral Anticoagulants in Patients With Atrial Fibrillation in the UK Primary Care
- Conditions
- Atrial Fibrillation
- Interventions
- Drug: Oral anticoagulant
- First Posted Date
- 2019-09-23
- Last Posted Date
- 2021-04-26
- Lead Sponsor
- Bayer
- Target Recruit Count
- 3739
- Registration Number
- NCT04099238
- Locations
- ๐ฌ๐ง
Many facilities, Multiple Locations, United Kingdom